Estamos no ar no ! Saiba mais

KVUE

Kenvue

KVUE

Deslistada

KVUE foi retirado da bolsa em 30 de outubro de 2026.

Voltar ao ranking

Sobre: Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Funcionários: 22.000

Bens de consumo básico Produtos domésticos e pessoais

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 28,9%

Neutro 53,3%

Negativo 17,8%

24/7 Wall Street

Kenvue Is Leaving the S&P 500: Here's What It Means for Investors

Kimberly-Clark is absorbing one of the most recognizable brand portfolios in consumer health, and the deal reshapes what investors own across three different indexes at once.

Kenvue Is Leaving the S&P 500: Here's What It Means for Investors

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4: S&P MidCap 400 constituent Okta Inc. (NASD: OKTA) will replace Kenvue Inc. (NYSE: KVUE) in the S&P 500, S&P SmallCap 600 constituent Glaukos Corp. (NYSE: GKOS) will replace Okta in the S&P MidCap 400, and McGrath RentCorp (NASD: MGRC) will replace Glaukos in the S&P SmallCap 600. S&P 500 constituent Kimberly-Clark (NASD: KMB) is acquiring Kenvue in a deal expected to be completed soon, pending final closing conditions.

Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Zacks Investment Research

Kenvue (KVUE) Surpasses Q3 Earnings Estimates

Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.28 per share a year ago.

Kenvue (KVUE) Surpasses Q3 Earnings Estimates

Kenvue Profit, Revenue Rise as Turnaround Efforts Continue

Kenvue reported higher profit and revenue as it works to turn around its business ahead of its $40 billion acquisition by consumer-products company Kimberly-Clark.

Kenvue Profit, Revenue Rise as Turnaround Efforts Continue

Kenvue Reports Third Quarter 2026 Results

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal third quarter ended September 27, 2026. “We are pleased to have delivered our fourth consecutive quarter of net and organic sales growth, with strong performance in Self Care and Essential Health, along with margin expansion and strong cash generation,” said Kirk Perry, Chief Executive Officer. “Our results reflect continued momentum from disciplined execution, ongoing productivity initiativ.

Kenvue Reports Third Quarter 2026 Results

Zacks Investment Research

Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors

KVUE's Q3 results are likely to benefit from brand-building, product innovation and cost savings, while inflation and cautious consumer spending pressure margins.

Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors

Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes

DALLAS, Oct. 27, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the extension of the expiration date of the offers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue Inc. (NYSE: KVUE) ("Kenvue") for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes"). Kimberly-Clark hereby extends such expiration date from 5:00 p.m.

Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes

24/7 Wall Street

4 Big-Name Dividend Stocks Paying Yields Most Blue Chips Can't Match

Four household names spread across pipelines, tobacco, banking, and consumer staples are paying yields that most blue chips never come close to, but a big yield number means nothing if the cash behind it runs dry.

4 Big-Name Dividend Stocks Paying Yields Most Blue Chips Can't Match

Zacks Investment Research

3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market

Clean beauty, innovation and digital shopping are reshaping the industry. Explore how ELF, EL and ULTA are adapting to changing consumer preferences.

3 Beauty Stocks to Explore as Consumer Preferences Reshape the Market

Kenvue to Announce Third Quarter 2026 Results on October 30, 2026

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a ce.

Kenvue to Announce Third Quarter 2026 Results on October 30, 2026

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™